雷蛇(01337.HK)高端旗艦外設於天貓和京東「雙11」銷量稱冠
雷蛇(01337.HK)披露在剛過去的「雙11」銷售表現出色,雷蛇高端旗艦外設於天貓和京東的銷量均排名第一,而高端電競椅類目在雙平臺的成交更按年增長2000%,累積訪問用戶量超500萬。
銷售亮點包括:遊戲滑鼠於天貓和抖音無線滑鼠熱銷榜位居榜首;Razer DeathAdder和Razer Basilisk X HyperSpeed亦分別於京東有線(滑鼠類目100-150元人民幣價格區間)和無線滑鼠的熱銷榜(滑鼠類目200-300元人民幣價格區間)中位居榜首。遊戲鍵盤Razer BlackWidow鍵盤榮登天貓V榜。遊戲耳機Razer Kraken X在京東遊戲耳機類目位居榜首。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.